Mizuho Cuts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $35.00

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price objective lowered by Mizuho from $37.00 to $35.00 in a research report released on Monday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Other analysts have also recently issued reports about the company. Guggenheim raised their target price on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, February 27th. TD Cowen increased their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Needham & Company LLC increased their target price on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.86.

Arcutis Biotherapeutics Trading Up 2.2%

Arcutis Biotherapeutics stock opened at $24.12 on Monday. Arcutis Biotherapeutics has a 52-week low of $11.86 and a 52-week high of $31.77. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -172.27 and a beta of 1.66. The firm has a 50-day moving average price of $26.92 and a two-hundred day moving average price of $24.03.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.03 by $0.10. The company had revenue of $129.50 million for the quarter, compared to analyst estimates of $110.79 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. Sell-side analysts expect that Arcutis Biotherapeutics will post -1.33 earnings per share for the current year.

Insider Activity

In other news, insider Patrick Burnett sold 11,500 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $28.94, for a total value of $332,810.00. Following the transaction, the insider owned 98,307 shares of the company’s stock, valued at $2,845,004.58. The trade was a 10.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Larry Todd Edwards sold 3,687 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $25.18, for a total transaction of $92,838.66. Following the completion of the sale, the insider owned 175,178 shares in the company, valued at $4,410,982.04. The trade was a 2.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 175,233 shares of company stock valued at $4,537,485 over the last quarter. Insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Jennison Associates LLC lifted its position in shares of Arcutis Biotherapeutics by 10.3% during the 3rd quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after acquiring an additional 1,144,714 shares during the last quarter. Suvretta Capital Management LLC raised its position in shares of Arcutis Biotherapeutics by 14.2% during the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in shares of Arcutis Biotherapeutics by 12.4% during the second quarter. Frazier Life Sciences Management L.P. now owns 9,874,511 shares of the company’s stock valued at $138,441,000 after purchasing an additional 1,089,227 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Arcutis Biotherapeutics by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company’s stock valued at $210,654,000 after purchasing an additional 107,846 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its position in shares of Arcutis Biotherapeutics by 4.9% in the 4th quarter. Polar Capital Holdings Plc now owns 5,556,169 shares of the company’s stock valued at $161,351,000 after purchasing an additional 257,415 shares during the period.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Pipeline catalyst — Arcutis announced enrollment of the first participant in a Phase 1a/1b study of ARQ‑234 (CD200R agonist) to assess safety/tolerability in healthy volunteers and adults with moderate‑to‑severe atopic dermatitis. This is a meaningful development catalyst for future valuation if the program advances. ARQ‑234 Phase 1a/1b Enrollment
• Neutral Sentiment: Fund activity — Baron Health Care Fund filed Q4 activity; filings didn’t show a decisive, headline‑driven change in ARQT ownership that would clearly move the stock on its own. Baron Fund Q4 Activity
• Neutral Sentiment: Short‑interest reports unreliable — multiple short‑interest entries in the feeds show 0 shares/NaN changes; treat those numbers as erroneous until exchange data confirms. No reliable short‑squeeze signal from current reports.
• Negative Sentiment: Clustered insider selling — Several insiders sold sizable blocks between Feb 27–Mar 2 (notable filings: Todd Watanabe ~37,349 shares; Masaru Matsuda, Patrick Burnett, CFO Latha Vairavan). Aggregated insider dispositions (tens of thousands of shares) likely weighed on sentiment and amplified selling. Representative filing (Watanabe): Watanabe Form 4 — CFO sale filing: CFO Form 4
• Negative Sentiment: Analyst downgrade / pessimistic note — Coverage in the newsfeed reported a downgrade and a pessimistic near‑term forecast that coincided with a sharp intraday drop; that broker action amplified selling pressure. Shares Down After Analyst Downgrade — related pessimistic forecast item: Mizuho Pessimistic Forecast

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.